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1. Introduction 
The clinical validation of several anti-angiogenic agents targeting the VEGF pathway for the 
treatment of metastatic colorectal cancer (Hurwitz et al., 2004), non-small cell lung cancer 
(Sandler et al., 2006), hepatocellular carcinoma (Llovet et al., 2008) and metastatic renal cell 
carcinoma (mRCC) (Motzer et al., 2009) has provided evidence that angiogenesis inhibition 
can lead to increased overall patient survival. Although these treatments achieve sustained 
tumor regression in isolated cases, the average clinical gains from individual therapeutics are 
measured in only weeks to months. In most patients, cancer progression resumes following 
initial disease stabilization as tumors acquire resistance to anti-angiogenic agents (Ellis and 
Hicklin, 2008; Rini and Atkins, 2009). In some disease, such as metastatic breast cancer (Miller 
et al., 2007), the clinical benefits from VEGF-targeted therapies appear marginal from the 
outset, while still other cancer types, such as melanoma (Hauschild et al., 2009) and pancreatic 
ductal adenocarcinoma (Kindler et al., 2007), appear to be refractory to anti-angiogenic drugs 
from the outset and are deemed “intrinsically” resistant (Bergers and Hanahan, 2008). 
Acquired and intrinsic resistance to VEGF-targeted therapies stem from multiple pro-
angiogenic mechanisms: VEGF signaling upregulation (Rini and Atkins, 2009); secretion of 
alternative angiogenic factors (Casanovas, 2011; Kopetz et al., 2010; Loges et al., 2010); 
acquisition of new blood vessels in an angiogenesis-independent manner via 
vasculogenesis, vessel co-option or vascular mimicry (Kerbel, 2008; Loges et al., 2010); and 
activation of stromal components such as myeloid cells and cancer associated fibroblasts, 
which can cooperate to rescue or expand the tumor vasculature (Bergers and Hanahan, 
2008; Crawford and Ferrara, 2009). To overcome acquired resistance mechanisms, some 
clinicians currently shift patients from one VEGF-targeted therapy to another and are able to 
achieve lasting clinical benefit at least in the case of metastatic renal cell carcinoma (mRCC), 
suggesting that upregulation of the VEGF signaling pathway itself is one of the major initial 
routes of resistance in this cancer type (Rini and Atkins, 2009). However, all cancers 
eventually acquire resistance to even the most potent VEGF receptor inhibitors, 
underscoring the need for additional anti-angiogenic therapies targeted at alternative 
signaling pathways to overcome these resistance mechanisms. 
In this chapter, we will review two signaling pathways that play critical functions at distinct 
phases of angiogenesis and against which experimental drugs are currently in development: 
the NOTCH and BMP9-ALK1 signaling axes. In each case, we will present the genetic and 
experimental evidence demonstrating the function of these signaling axes in angiogenesis, 
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the signal transduction events they mediate during angiogenesis and the pre-clinical 
evidence indicating that targeted inhibition of these pathways leads to the disruption of 
tumor angiogenesis and decreased tumor growth.  
2. Function of NOTCH signaling in angiogenesis 
Named after the notched wing appearance of its Drosophila phenotype (Mohr, 1919; 
Morgan and Bridges, 1916), the NOTCH pathway is a highly conserved signaling system 
that plays a role in multiple critical processes, including stem cell maintenance, pattern 
formation, and cell fate determination. In vertebrates, this signaling system is comprised of 
four NOTCH receptors, and five trans-membrane ligands. This section will summarize the 
data that demonstrate the role of individual members of this signaling pathway in vascular 
development and discuss the evidence that suggests that NOTCH signaling may represent 
an attractive point of therapeutic intervention for angiogenic therapy.  
2.1 Expression of NOTCH receptors and ligands in endothelial cells and in tumors 
Expression analysis of the NOTCH signaling pathway in human cancer samples provides 
encouraging evidence of a role for NOTCH signaling in human disease. Expression of the 
NOTCH ligand Delta-like 4 (DLL4) is upregulated in human breast cancer and not found in 
normal breast tissue (Li et al 2007). Similar studies have also demonstrated an upregulation 
of DLL4 expression in the tumor endothelium of clear cell renal cell carcinoma (CC-RCC) 
patients compared to normal kidney vasculature (Figure 1; Patel 2005) as well as in bladder 
carcinoma compared to normal bladder tissue (Patel et al., 2006). Mouse studies corroborate 
a role for DLL4 in the tumor vasculature. In a mouse reporter line where LacZ expression is 
driven by the DLL4 promoter, there is preferential expression in the tumor vasculature of 
implanted Lewis lung carcinoma tumors compared to the adjacent normal vasculature. 
Interestingly, a VEGF-Trap molecule that induces a VEGF signaling blockade effectively 
blocks the upregulation of DLL4 in the tumor vasculature of C6 glioma xenograft tumors, 
suggesting that DLL4 upregulation may be VEGF dependent (Gale et al., 2004; Noguera-
Troise et al., 2006). 
The NOTCH ligands may also signal from the tumor itself to the vasculature. Jagged1 
(JAG1) expression in head and neck squamous cell carcinoma (HNSCC) cell lines is 
upregulated in response to multiple growth factors, such as HGF, EGF, and TGF-alpha, 
pathways that are commonly altered in human cancer. In an HNSCC xenograft model, 
tumor expressed JAG1 enhanced neovascularization and tumor growth in vivo, and 
correlated with vessel content and disease progression, suggesting JAG1 may signal from 
the tumor to the tumor vasculature via murine NOTCH expressed on ECs (Zeng et al., 
2005). There have also been reports of tumor expression of DLL4 in colorectal cancer (Jubb et 
al., 2009), although it has been hypothesized to play a direct role in cancer stem cell survival 
rather than tumor signaling to the endothelium (Hoey et al., 2009). 
2.2 Functional role of NOTCH receptors in developmental angiogenesis 
The phenotypes associated with genetic alteration of individual components of the NOTCH 
signaling pathway validate a role for multiple pathway members in embryonic vascular 
development. Each of the NOTCH receptors is expressed in the mouse vasculature and 
deletion of some individual NOTCH receptors show embryonic lethality, demonstrating 
non-overlapping functions during development. For example, NOTCH1 null mice are  
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Fig. 1. Differential expression of DLL4 in renal cancer. 
In situ analysis (A) or RT-PCR (B) demonstrates higher relative expression (up to nine-fold) 
of human DLL4 in CC-RCC samples compared to normal kidney tissue. (C) DLL4 
expression correlates with elevated VEGF-A expression. ©Adapted and reprinted by 
permission from the American Association for Cancer Research: Patel et al, Up-regulation of 
delta-like 4 ligand in human tumor vasculature and the role of basal expression in 
endothelial cell function, Cancer Res, 2005, (19) 65: 8692. 
non-viable due to severe vascular defects and impaired somitogenesis with extensive cell 
death resulting in lethality by embryonic day 9.5 (Conlon et al., 1995) -10.5 with complete 
resorption by d11.5 (Swiatek et al., 1994). Endothelial cell specific deletion of NOTCH1 has a 
similar phenotype, demonstrating the critical endothelial compartment function of 
NOTCH1 in early vascular development (Limbourg et al., 2005). While the NOTCH4 
knockout mouse is viable, compound loss of NOTCH1 and NOTCH4 shows a more 
profound vascular phenotype than deletion of either single gene alone (Krebs et al., 2000), 
suggesting a possible NOTCH1 redundancy for NOTCH4 in development. 
NOTCH2 is also expressed in the mouse vasculature, most notably in the developing heart 
(Loomes et al., 2002). However, mice expressing a NOTCH2 deletion mutant that lacks all but 
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one of the ankyrin repeats in the N2ICD die prior to NOTCH2 heart expression at d11.5 with 
abnormalities observed in the neuroepithelium and cranial ganglia cells, as well as the optic 
and otic vesicles (Hamada et al., 1999). A NOTCH2 hypomorph allele causes perinatal lethality 
due to defects in the glomerular development in the kidney (McCright et al., 2001). Taken 
together, these data suggest that NOTCH2 may have non-vascular roles in development. 
Despite expression of NOTCH3 in the mouse heart (Loomes et al., 2002), NOTCH3 null mice 
are viable, fertile and show no overt phenotype either alone, and unlike NOTCH4, does not 
show increased vascular defects on a NOTCH1 null background (Krebs et al., 2003). A 
detailed analysis of the NOTCH3 phenotype indicates that this receptor may play a role in 
arterial identity of vascular smooth muscle cells, as distal arteries exhibit structural lesions 
and defective arterial myogenic responses (Domenga et al., 2004). In humans, NOTCH3 
mutations are associated with Cerebral Autosomal Dominant Arteriopathy with Subcortical 
Infarcts and Leukoencephalopathy (CADASIL), an adult onset vascular disorder caused by 
systemic vascular lesions that result in a myriad of symptoms, including recurrent ischemic 
strokes (Joutel et al., 1996). These mutations do not seem to affect ligand/receptor 
interaction nor do they disrupt subsequent signaling (Haritunians et al., 2002). The 
mutations allow accumulation of a soluble NOTCH3 ECD (Joutel et al., 2000), and this could 
locally interfere with signaling of multiple intact NOTCH receptors and their ligands as 
there is substantial binding promiscuity among NOTCH receptors and ligands. 
2.3 Functional role of NOTCH ligands in developmental angiogenesis 
Knockout of JAG1 in the mouse results in embryonic lethality by E10 -10.5 and can be 
identified by hemorrhage and the lack of large blood vessels in the yolk sac, reminiscent of 
the NOTCH1 null phenotype. Additional vascular defects and hemorrhage are also present 
in the cranial area and there is an overall loss of vessel branching and reduced vessel 
diameter (Xue et al., 1999). Like the NOTCH1 deletion, the phenotype is similar when the 
knockout is restricted to the endothelial cell compartment suggesting that the early lethality 
is due to JAG1 expression in the vasculature (High et al., 2008). Detailed examination shows 
that vascular smooth muscle cell (VSMC) markers are severely diminished despite intact 
NOTCH signaling in the endothelial cells themselves. The primary role of JAG1 may 
therefore be to signal to the VSMC, and other ligands may be able to compensate for the loss 
of JAG1-triggered signaling in the endothelial cells. Other studies using conditional loss or 
overexpression of JAG1 suggest that JAG1 plays a proangiogenic role in the presence of 
other ligands in the developing retina and can act as a partial antagonist to DLL4 to 
modulate NOTCH pathway signaling (Benedito et al., 2009). In humans, JAG1 mutations 
have been associated with Allagille syndrome (AGS), which has a variety of symptoms 
including reduced numbers of intrahepatic bile ducts, cardiac defects (including pulmonary 
artery stenosis and hypoplasia, pulmonic valve stenosis and tetralogy of Fallot), skeletal 
defects, ophthalmological abnormalities, renal and pancreatic abnormalities, and 
intracranial bleeding. Although mutations in NOTCH2 have not been associated with AGS, 
combined mutations of both NOTCH2 and JAG1 best recapitulate the human pathology of 
AGS in the mouse (McCright et al., 2002). 
DLL4 is expressed throughout the vascular endothelium, most notably in the endothelial 
cells of actively growing capillaries at the leading front of the superficial vascular plexus, 
while mature capillaries have lower levels of DLL4 expression as analyzed in situ (Shutter et 
al., 2000) or by reporter construct (Lobov et al., 2007). Over time, DLL4 expression decreases 
in mature veins but increases in the arteries. DLL4 inactivation results in an early lethality 
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and haploinsufficiency by E9.5 in some mouse strains. DLL4 knockout embryos exhibit an 
avascular yolk sac, arterio-venous malformations (AVMs), growth retardation, and an 
overall lack of major arteries and vascular remodeling (Krebs et al., 2004) In rare cases of 
heterozygote survival, defects are also observed in the developing retina characterized by 
enhanced angiogenic sprouting and endothelial cell proliferation, which is a hallmark of a 
DLL4 blockade (Lobov et al., 2007).  
Delta-like 1(DLL1) has been reported to be expressed in the endothelium of the developing 
embryo in both arteries and veins (Beckers et al., 1999). DLL1 is detectable in fetal arterial 
endothelial cells beginning at embryonic day 13.5, and is a critical regulator of arterial 
identity. Disruption of DLL1 leads to lethality by E12 with aberrant somite 
compartmentalization and hemorrhagic events (Hrabe de Angelis et al., 1997). Loss of DLL1 
in the mouse also leads to a downregulation of VEGF receptor 2 (VEGFR2) and neuropilin 
(NRP) expression as well as a reduction in the levels of activated NOTCH1 receptor, despite 
the expression of DLL4 and JAG1 in the endothelium (Sorensen et al., 2009). The role of 
DLL1 is not restricted to the developing embryo, as heterozygous adult mice display 
impaired arteriogenesis after induction by ischemia (Limbourg et al., 2007). 
Knockout of the Jagged2 (JAG2) gene in mouse die at birth due to cleft palate and lack 
observable defects in the vascualture. Future studies using a conditional allele may 
illuminate a role of JAG2 in the vasculature of the adult mouse (Xu et al., 2010). A targeted 
Delta-like 3 (DLL3) knockout mouse is viable, but homozygous mutants have growth 
defects with disorganized vertebrae and costal defects resulting from defective 
segmentation in the embryo and delayed and irregular somite formation. Similarly, two 
viable spontaneous mutations of DLL3, pudgy and omagari, have abnormal formation and 
patterning of somites. Although clearly important for normal development, neither the 
JAG2 nor the DLL3 null mice have apparent signs of an angiogenic defect. However, this 
does not exclude a vascular role beyond their essential functions in development. 
2.4 Overview of NOTCH signaling 
The four NOTCH receptors are single pass transmembrane proteins with a large number 
(25-29) of epidermal growth factor-like (EGF-like) motifs that are repeated throughout their 
extracellular domains (ECD) (see Kopan and Ilagan, 2009 for a recent comprehensive 
review). They are each synthesized as a proreceptor before cleavage by a furin-like protease 
during their transport to the surface (Blaumueller et al., 1997; Logeat et al., 1998). The ECDs 
of NOTCH receptors also contain 3 LIN12/NOTCH repeat (LNR) domains that are 
noncovalently linked to the rest of the receptor through a heterodimerization (HD) domain. 
The HD and LNR domains collectively make up the negative regulatory region (NRR), 
which overall prevents activation of the receptor in its non-ligand bound state (Sanchez-
Irizarry et al., 2004).  
The classical NOTCH ligands are also single pass transmembrane proteins. (Figure 2) The 
ligands have multiple EGF repeats as well as a Delta, Serrate, and Lag-z (DSL) domain that 
is essential for interaction with the NOTCH receptors. Jagged ligands distinguish 
themselves from the Delta-like ligands by an additional cysteine rich domain (reviewed by 
Kopan, 2009). There are also non-classical ligands that can activate NOTCH receptors in 
specific contexts, such as the Delta/NOTCH-like EGF-related receptor (DNER), which acts 
as a NOTCH ligand in neurons for glial cell differentiation (Eiraku et al., 2005) or 
F3/cortactin, which is involved in NOTCH activation during oligodendrocyte maturation 
(Hu et al., 2003). Ligands and receptors are proposed to be expressed on opposing cells and  
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Fig. 2. Diagram of the NOTCH ligands and receptors. 
A. The NOTCH ligand family has five distinct transmembrane ligands, each encoded by its 
own gene. The extracellular domains of all the receptors contain a signal peptide (SP), 
multiple EGF repeats, and a Delta/Serrate/Lag-2 (DSL) as well as a transmembrane (TM) 
domain. The Jagged ligands also have a cysteine rich domain. All ligands have a small 
intracellular domain as well. B. The NOTCH receptor family has four distinct 
transmembrane receptors, each encoded by its own gene. The extracellular domains of all 
the receptors contain multiple EGF repeats as well as an LNR domain which protects the 
receptors from cleavage and thereby preventing activation. Ligand binding is thought to be 
mediated by EGF repeats 11-13. The intracellular domains contain a RAM domain, six ANK 
repeats, two NLS sequences, and a PEST domain to regulate the stability of the protein. 
NOTCH3 has a weak transcriptional activation domain (TAD) compared to other receptor 
family members.  
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operate as a short-range signaling system. When a NOTCH ligand binds to a NOTCH 
receptor, the interaction induces a conformational change in the NRR region allowing 
exposure of additional cleavage sites (reviewed in Gordon et al., 2008). The first cleavage is 
mediated by ADAM-type metalloproteases on the ECD side of the protein (Gordon et al., 
2007). Nicastrin, a transmembrane glycoprotein protein in the presenilin/-secretase 
protease complex, helps mediate the second cleavage by docking NOTCH into the protease 
(Chen et al., 2001), resulting in the release of the NOTCH intracellular domain (NICD) 
(Struhl and Greenwald, 1999). The NICD contains a nuclear localization signal (NLS) that 
regulates translocation into the nucleus (Figure 3) (Schroeter et al., 1998). 
 
 
Fig. 3. Canonical NOTCH receptor signaling. 
Ligand presentation by an adjacent cell can activate the receptor by promoting two 
sequential cleavages (denoted by scissors) by the TACE family of proteases and -secretase. 
These cleavages liberate the NOTCH receptor intracellular domain and allow it to 
translocate to the nucleus. NICD then interacts with the CSL family of transcription factors 
and induces expression of NOTCH target genes. 
The NICD of all four NOTCH receptors contains a regulation of amino acid (RAM) domain, 
ankyrin (ANK) repeats, a nuclear localization signal (NLS) (Lieber et al., 1993), and a 
proline, glutamate, serine, threonine (PEST) domain (Figure 2). Cdk8 directly 
phosphorylates the PEST domain in all NICDs, which then become substrates for the 
nuclear ubiquitin ligase Sel10, regulating NICD turnover. (Fryer et al., 2002; Fryer et al., 
2004; Oberg et al., 2001). Prior to destruction, the NICD interacts via its ANK repeats with 
the DNA binding protein CBF1/Drosophila Su(H)/C.Elegans LAG-1 (CSL), which, in the 
absence of NOTCH, associates with co-repressors and histone deacetylases to prevent 
transcription of key gene targets (Jarriault et al., 1995). Once NICD is present and binds to 
CSL, the co-repressors are displaced allowing recruitment of mastermind (MAML) and 
conversion into a transcriptional activation complex. The co-regulator SKIP and histone 
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deacetylase p300 are also recruited to the same promoters (Wallberg et al., 2002; Zhou et al., 
2000). This allows the transcription of members of the Hes and Hey family of transcriptional 
repressors (Ohtsuka et al., 1999), reviewed in (Iso et al., 2003). The strength of the 
transcriptional signal varies among family members and seems to depend upon cofactor 
association as well as binding site orientation (Ong et al., 2006). 
NOTCH signaling between receptors and ligands can be further regulated by post-
translational glycosylation of the receptors and ligands which contain multiple potential 
sites for N- and O- linked glycosylation. The Fringe family of glycosyltransferases can 
mediate O-fucose elongation on the NOTCH ECD (Moloney et al., 2000) thereby changing 
affinity of NOTCH receptors for their ligands. For example Fringe modification of NOTCH1 
increases activation by Delta1 but decreases activation by JAG1 (Yang et al., 2005). Dynamic 
fringe family expression can thereby substantially modify NOTCH signaling (reviewed by 
(Haines and Irvine, 2003). Rumi has also been identified in Drosophilla as an enzyme that 
can add O-glucose to the NOTCH ECD and may affect NOTCH signaling by enhancing 
cleavage and activation of NOTCH by its ligands (Acar et al., 2008). 
2.5 Preclinical data using pharmacological inhibitors targeting NOTCH signaling 
The genetic data ascribing a key role for NOTCH signaling in angiogenesis has encouraged 
multiple groups to create molecules to specifically inhibit NOTCH signaling and evaluate 
their subsequent effects on the tumor vasculature. Such agents include soluble DLL4 
(SolDLL4) fused to Fc and neutralizing antibodies specific to DLL4 or NOTCH1 that inhibit 
the receptor/ligand interaction (Funahashi et al., 2008; Noguera-Troise et al., 2006; Ridgway 
et al., 2006; Wu et al., 2010). These agents have demonstrated an anti-tumor effect in a broad 
spectrum of xenograft models, including those with intrinsic or acquired resistance to VEGF 
therapy. Examination of the tumor vasculature with all agents revealed an increase in 
sprouting leading to an overall expansion of non-productive vasculature, as evidenced by 
greater hypoxia in the tumor itself and decreased perfusion of these new vessels. 
Subsequent studies using live-cell imaging suggest that the aberrant sprouting is due to the 
fact that tip cell positioning is dynamic and migration of vessel stalk cells creates 
competition for the tip position among ECs. Regulation and organization of the vessel is 
determined by DLL4 expression, via modulation by VEGF receptor 1 and 2 (VEGFR1 and 
VEGFR2) levels, to allow tip formation only towards the highest concentrations of VEGF-A. 
Disruption of DLL4/NOTCH signaling using pharmacological inhibitors subsequently 
disrupts the ability of the vessel to organize (Jakobsson et al., 2010).  
Blockade of DLL4 signaling has been reported to be enhanced with blockade of other 
angiogenic signaling pathways. Notably, the efficacy of anti-DLL4 treatment was increased 
upon the addition of agents designed to inhibit VEGF signaling, either with an anti-VEGF-A 
antibody (Ridgway et al., 2006), or a soluble VEGFR2-Fc fusion protein (Noguera-Troise et al., 
2006). As bevacizumab is already an approved agent for human use, there is clear potential for 
use as a clinical combination. A recent study has also demonstrated that inhibition of EphrinB4 
signaling by a soluble EphB4 albumin fusion protein in combination with either allelic deletion 
or a soluble DLL4-Fc fusion construct could also enhance efficacy in the RipTag model, a 
highly angiogenic model of pancreatic islet carcinogenesis (Djokovic et al., 2010).  
2.6 Potential preclinical toxicities associated with chronic NOTCH signaling inhibition 
Although these data suggest that NOTCH signaling is an attractive target for therapeutic 
intervention in tumor angiogenesis, there may be substantial side effects associated with short 
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and long term blockade of NOTCH signaling. Several studies suggest that NOTCH signaling 
acts as a tumor suppressor in specific tissues. For example, skin specific ablation of NOTCH1 
results in hyperproliferation of the basal epidermal layer in young mice and epidermal and 
corneal hyperplasia in older mice (Nicolas et al., 2003). A recent study has also demonstrated 
that NOTCH1 can act as a tumor suppressor in a K-Ras driven model of pancreatic cancer. 
Pancreas specific K-RasG12D expression causes early stage lesions of pancreatic cancer, 
reminiscent of ADM/Tc, PanIN1A or PanIN1B stages in human disease (Hingorani et al., 
2003). Pancreas specific NOTCH loss in this background significantly accelerates pancreatic 
lesions and produced a more advanced grade (PanIN1B to PanIN2), suggesting that loss of 
NOTCH results in increased tumor incidence and progression (Hanlon et al., 2010). In both 
cases, increased proliferation was observed as assessed by Ki67 staining of affected tissue. 
NOTCH signaling may also have a tumor suppression role in myeloid leukemia due to altered 
fate specification. Deletion of NOTCH1 and NOTCH2 or Nicastrin results in a murine form of 
chronic myelomonocytic leukemia (CMML) due to accumulation of granulocyte/monocyte 
progenitors. Loss of NOTCH dependent inhibition of genes that specify myelomonocytic fate 
for the blood cells causes resultant pathology. Interestingly, mutations in NOTCH signaling 
were found in 5/42 patient samples with CMML (Klinakis et al., 2011) suggesting that this 
may be relevant to the development of human disease.  
Another intriguing genetic study that demonstrated the effects of long term NOTCH loss used 
a model in which the endogenous NOTCH1 gene was replaced with NOTCH1-Cre fusion 
protein (Vooijs et al., 2007). When crossed with a mouse containing a floxed NOTCH1 allele, it 
allows progressive inactivation of NOTCH1 dependent signaling in its physiologic context, i.e. 
as NOTCH1 is activated, it is lost. Beyond a broad effect on overall survival due to 
hemorrhage and vascular tumors, 11 out of 13 mice in this system demonstrated aberrations in 
multiple organs, including the liver, ovary, testis, skin, lymph nodes, uterus, and colon. The 
liver in particular, was the organ most affected by NOTCH1 activated loss and had evidence of 
hemangiomas and proliferation specifically associated with NOTCH1 loss (Liu et al., 2011).  
In other preclinical studies, pharmacological agents causing long term blockade, such as an 
anti-DLL4 antibody, also caused unexpected proliferative effects in select tissues (Yan et al., 
2010). Dose dependent ulcerating subcutaneous tumors (mouse) as well as sinusoidal 
dilation and centrilobular hepatocyte atrophy in the liver (mouse, rat, monkey) was 
observed. It was also noted that similar liver effects were seen with both an anti-NOTCH1 
antibody and a -secretase inhibitor, which would inhibit processing or activation of all 
NOTCH recetpors, suggesting that the effects were likely pathway associated. However, 
impact on overall survival was not observed as was seen in the genetic study, possibly due 
to shorter exposure as compared to genetic loss. It is unknown if the other vascular beds that 
were described to be affected in the genetic study were affected by antibody inhibition as 
they were not discussed. Interestingly, there may be mechanisms to counteract NOTCH 
signaling induced proliferation. For example, hepatic lesions caused by DLL4 inhibition 
were prevented when combined with systemic Ephrin B2/EphB4 inhibition, (Djokovic et al., 
2010). As mentioned earlier, this combination enhanced anti-DLL4 efficacy, and that 
combination therapy may be a possible approach to mitigate NOTCH pathway associated 
toxicities while preserving anti-tumor effects. 
2.7 Clinical perspectives 
Despite the possible toxicities described above, the compelling preclinical efficacy data 
generated with neutralizing agents to DLL4 and NOTCH1 have encouraged efforts to 
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evaluate these agents in the clinic. Currently two companies have active clinical trials that 
target DLL4 (www.clinicaltrials.gov). OMP-21M18 (Oncomed Pharmaceuticals) is a 
neutralizing anti-DLL4 mAb that is currently in Phase 1 and 1b clinical trials in combination 
with chemotherapy. OMP-21M18 is specific for human DLL4, and preclinical data with this 
antibody demonstrates a direct anti-tumor effect for primary human xenografts that express 
huDLL4. However, OMP-21M18 combined with an antibody that recognizes muDLL4 
demonstrated increased efficacy, suggesting that DLL4 signaling has a role in both tumor 
and stroma in primary human xenograft growth (Hoey, 2009). A second human anti-DLL4 
mAb, REGN-421, created by Regeneron pharmaceuticals, is also in Phase 1 clinical trials. 
Given the preclinical data, there may be benefit to combination of an agent targeting DLL4 
with bevacizumab. A recent retrospective analysis demonstrates that DLL4 expression, 
along with VEGF-C and neuropilin-1, indicated a poor response to bevacizumab treatment 
and may be a path of resistance in human disease (Jubb et al., 2011). 
3. Function of ALK1 / Endoglin signaling in angiogenesis 
A second angiogenic signaling axis with potential for therapeutic intervention is the 
ALK1/Endoglin pathway. In recent years, therapeutics directed at the ALK1/Endoglin 
signaling axis have entered phase 1 and 2 clinical trials, marking a clinical transition for a 
field of research dating back more than 20 years with the cloning of Endoglin (ENG or 
CD105) and ALK1 (Attisano et al., 1993; Gougos and Letarte, 1990). ENG, a homo-dimeric 
membrane glycoprotein highly expressed in endothelial cells (Gougos and Letarte, 1988), 
has homology to betaglycan and is capable of binding several cytokines of the TGF- 
super family, leading to its classification as a Type III TGF co-receptor. ALK1, the 
product of the Activin receptor-like kinase 1 gene (ACVRL1), is an endothelial-specific 
serine/threonine kinase belonging to the Type I TGF receptor family (Attisano et al., 
1993). Together, ENG and ALK1 define a signaling receptor complex for the BMP9 and 
BMP10 cytokines at the surface of endothelial cells. ENG and ALK1 are required for 
angiogenesis and vascular morphogenesis and anti-ENG and anti-ALK1 targeted agents 
have the potential to disrupt tumor angiogenesis independently or cooperatively with 
anti-VEGF treatment.  
3.1 Normal and tumor endothelial expression of ENG and ALK1 
ENG and ALK1 are both preferentially expressed in endothelial cells. During development, 
ENG and ALK1 present very similar expression patterns in areas of vasculogenesis (yolk sac, 
early embryonic vasculature) and angiogenesis (throughout the late embryonic vascular 
endothelium) (Jonker and Arthur, 2002; Roelen et al., 1997; Seki et al., 2003). ENG is detected 
in veins, liver sinusoidal endothelial cells and arteries, while ALK1 is only detected in 
developing arteries, suggesting a role in arterial differentiation (Jonker and Arthur, 2002; 
Seki et al., 2003). In the adult, both transcripts are weakly detected in the microvasculature 
of several organs including the lung (Miller et al., 1999; Panchenko et al., 1996; Seki et al., 
2003) but the ENG protein is readily detected in the liver and kidney microvasculature 
(Minhajat et al., 2006). ENG protein expression is elevated in endothelial cells when 
angiogenesis is activated during wound repair and chronic inflammation (Torsney et al., 
2002). Protein expression of ENG and ALK1 is induced in the endothelium of nearly all solid 
tumors (Burrows et al., 1995; Hu-Lowe et al., 2011; Miller et al., 1999; Minhajat et al., 2006; 
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Wang et al., 1993) (Fig. 4). ENG is also detected in cell types other than endothelial cells, 
such as activated monocytes and at the surface of cancer cells in melanoma and leukemia 
(Altomonte et al., 1996; Fonsatti et al., 2001; Gougos and Letarte, 1988), while ALK1 is also 
detected in mesenchymal cells of multiple organs and in trophoblast giant cells during 
embryogenesis (Roelen et al., 1997). 
 
 
Fig. 4. Differential expression of ENG in tumor endothelial cells.  
In contrast to CD31 staining, an endothelial cell marker detected in both the normal colonic 
mucosa and in the vasculature of colon tumors, ENG is detected at much higher levels in the 
tumor vasculature and not in the normal colonic vasculature (Dallas et al., 2008). ©Adapted 
and reprinted by permission from the American Association for Cancer Research: Dallas et 
al, Endoglin (CD105): A marker of tumor vasculature and potential target for therapy, Clin 
Cancer Res, 2008, 14(7): 1933.  
The relative specificity of ENG and ALK1 expression in endothelial cells and their induction 
in cancer-associated endothelial cells stem from several mechanisms. First, ENG and ALK1 
share a combination of transcription factor binding sites with other endothelial-specific 
genes such as PECAM1 and VEGFR2 representing a possible endothelium transcriptional 
code (Garrido-Martin et al., 2010). Second, ENG is a HIF-1 target gene induced by hypoxia, 
(Li et al., 2003; Sanchez-Elsner et al., 2002), a near universal hallmark of cancer (Hanahan 
and Weinberg, 2011), and the ALK1 promoter contains several HIF-1binding motifs 
(Garrido-Martin et al., 2010). Third, ALK1 is induced by BMP4 (Shao et al., 2009), a cytokine 
required for vascular development (David et al., 2009). Finally, ENG transcription is induced 
by TGF (Sanchez-Elsner et al., 2002) and BMP9 signaling (David et al., 2007) through 
numerous SMAD-binding elements in the ENG promoter. 
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3.2 Hemorrhagic Hereditary Telangectasia: a vascular genetic disorder linked to ENG 
and ALK1 loss-of-function 
Hemorrhagic Hereditary Telangectasia (HHT) is a rare autosomal dominant genetic 
disorder characterized by vascular abnormalities in the skin, brain, lung, liver and gastro-
intestinal tract resulting in the dilatation of post-capillary venules, disappearance of 
capillary beds, and AVMs (Fig. 5 A-B) (Lebrin and Mummery, 2008). Affected individuals 
suffer benign skin and mucosal dilatations (telangectasia), nosebleeds and more severe 
hemorrhage in affected organs (Guttmacher et al., 1995). Most subjects affected with HHT 
have been linked to heterozygous mutations in ENG (McAllister et al., 1994) or ALK1 
(Johnson et al., 1996) and are classified as HHT1 or HHT2 respectively. In most cases of 
HHT1, mutations generate null alleles of ENG leading to reduced expression of the ENG co-
receptor, indicating that haploinsufficiency is the underlying genetic mechanism of disease 
(Fernandez et al., 2005; Pece-Barbara et al., 1999). For HHT2, the affected ALK1 allele usually 
contains missense point mutations in the ALK1 kinase domain. The majority of these 
mutations lead to normal expression of ALK1 but to an absence of signal transduction from 
the BMP9 cytokine (Ricard et al., 2010) (see Signaling section 3.3). Thus mechanistically, 
HHT2 is likely caused by ALK1 haploinsufficiency. 
Mouse models carrying heterozygous genetic deletions of ENG or ALK1 genes recapitulate 
the haploinsufficient pathological features of HHT such as telangectasias and AVMs 
(Bourdeau et al., 1999; Srinivasan et al., 2003; Torsney et al., 2003). In ENG or ALK1 
homozygous mutant embryos, embryonic and yolk sac vascular development proceed 
normally until day E8.5 (Li et al., 1999; Urness et al., 2000). Hence, neither gene is required 
for vasculogenesis, the process of endothelial cell differentiation from mesodermal 
precursors, their assembly into primitive vascular networks and the coalescence of 
angioblasts to form the endothelial tubes of the dorsal aorta and the cardinal vein (Arthur et 
al., 2000; Bourdeau et al., 1999; Li et al., 1999; Urness et al., 2000). However, between E9.0 
and E9.5, abnormal vascular shunts reminiscent of AVMs appear in both ALK1 and ENG 
mutant embryos, connecting the dorsal aorta and the cardinal vein and causing blood flow 
shunts in the embryo (Fig. 5C) (Li et al., 1999; Sorensen et al., 2003; Urness et al., 2000). The 
maturation of the primitive endothelial network of the yolk sac through angiogenesis also 
fails to occur in ENG or ALK1 mutant embryos, leading to the disappearance of the vitelline 
vasculature in both genotypes by E10.5 (Li et al., 1999; Urness et al., 2000). ENG and ALK1 
mutant embryos also present severe defects in heart development as both genes are required 
for heart valve formation (Arthur et al., 2000; Bourdeau et al., 1999). The angiogenesis 
defects appear to be primary defects and not secondary heart phenotype defects, since the 
vascular malformations in ENG and ALK1 mutant embryos occur before the onset of heart 
development phenotypes (Sorensen et al., 2003). 
Angiogenesis defects in ALK1 and ENG mutant embryos result from the failure of 
endothelial cell reorganization leading to abnormal vessel shunting, but also from profound 
defects in perivascular smooth muscle cells (VSMC) and pericyte recruitment around 
endothelial cells, leading to vessel fragility and hemorrhaging (Li et al., 1999; Torsney et al., 
2003; Urness et al., 2000). Thus, both genes are required for two defining aspects of 
angiogenesis: endothelial network remodeling and vascular morphogenesis through 
recruitment of pericytes (Risau, 1997), essential support cells for the formation and 
maintenance of the vasculature (Bergers and Song, 2005). 
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Fig. 5. Phenotypic consequences of loss of ENG or ALK1 function. 
A. Normal dermal vasculature: well-differentiated veins and arteries are separated by 
micro-vascular capillary beds. B. Hereditary Hemorrhagic Telangectasia (HHT) subjects 
present with enlarged vessels, disappearance of micro-vascular capillary beds and arterio-
veinous malformations (AVM) leading to hemorrhage (Guttmacher et al., 1995). C. Mouse 
embryos carrying ENG or ALK1 mutations present similar defects: shunting of the 
circulation (upper panels), due to the fusion between the dorsal artery (DA) and the cardinal 
vein (CCV) (lower panels) (Sorensen et al., 2003). © Adapted and reprinted by permission 
from the Massachusetts Medical Society: Guttmacher et al, 1995 Hereditary Hemorraghic 
Telangectasia, NEJM, 1995, (333) 14: 919, and from Elsevier: Sorensen et al, 2003, Loss of 
distinct arterial and venous boundaries in mice lacking Endoglin, Dev Biol 261: 236-7. 
3.3 Signal transduction through ALK1 and ENG 
Several alternative models have been proposed regarding the identity of the cytokine 
capable of triggering physiological ALK1/ENG signaling in endothelial cells, and the type 
of SMAD response these cytokines trigger. In the following sections, we will review these 
models and explain why we favor the BMP9/ALK1/ENG/SMAD1-5 signaling model. 
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3.3.1 “Cross-over” TGF/ SMAD1-5 signaling model 
Initial studies describing ENG and ALK1 indicated that the two proteins could be part of a 
TGF receptor complex. Over-expressed ENG and ALK1 were found in protein complexes 
with TGF receptor 2 (TBR2) and radio-labeled TGF1 (Attisano et al., 1993; Cheifetz et al., 
1992) and endogenous complexes containing ENG, TBR2 and radio-labeled TGF1 were 
found in primary endothelial cells (Cheifetz et al., 1992; Yamashita et al., 1994). The finding 
that TGF could induce SMAD1-5 phosphorylation in Mouse Embryonic Endothelial Cells 
(MEEC) and Bovine Aortic Endothelial Cells (BAEC) through a signaling complex 
containing ENG, ALK1, ALK5 and TBR2 led to a model of “cross-over” TGF signaling, 
whereby TGF/ALK1 signaling antagonized TGF/ALK5 signaling in endothelial cells (Fig. 
6A) (Goumans et al., 2003; Goumans et al., 2002; Lebrin et al., 2004; Oh et al., 2000). These 
results were unexpected since TGF was thought to be incapable of signaling through BMP 
Type I receptors such as ALK1. Until then, the “canonical” model of TGF signaling axis 
postulated that ALK5 was the only Type I receptor for TGFand that TGF exclusively 
signaled via phosphorylation of SMAD2-3 (Massague, 2000) (Fig. 6B). Several subsequent 
studies have shown that immortalized or transformed cells could display a non-canonical 
“cross-over” TGF signaling pathway leading to SMAD1-5 phosphorylation via BMP Type I 
receptors (Daly et al., 2008; Finnson et al., 2008; Liu et al., 2009). This transition to “cross-
over” TGF/SMAD1-5 signaling from “canonical” TGF/SMAD2-3 signaling could explain 
how cancer cells switch from an anti-proliferative to a pro-invasive TGF response in the 
course of malignant cellular transformation (Liu et al., 2009). 
Thus, while there is no doubt that “cross-over” TGF/SMAD1-5 signaling has been detected 
in a number of immortalized and transformed cell lines and in some mesenchymal cell types 
(Wrighton et al., 2009), the evidence for such a signaling axis existing in endothelial cells 
rested entirely on results obtained in MEEC and BAEC (Goumans et al., 2002). However, 
given that MEEC cells are immortalized through infection with a retrovirus encoding the 
polyoma middle T oncoprotein (Larsson et al., 2001), it is unlikely that they represent a 
normal and physiological endothelial cell type. In addition, the observation that primary 
endothelial BAEC cells exhibit TGF/SMAD1-5 signaling (Goumans et al., 2002) could not 
be reproduced (Scharpfenecker et al., 2007; Shao et al., 2009) and TGF/SMAD1-5 signaling 
could not be detected in primary human endothelial cells (David et al., 2007; Shao et al., 
2009), suggesting that the “cross-over” TGF/SMAD1-5 signaling axis may only be detected 
in immortalized endothelial cell types. 
In vivo evidence also cast doubt on the proposed model of TGF as the key cytokine 
functioning upstream of ALK1/ENG/SMAD1-5 signaling in endothelial cells. Initially, 
because ALK1, ALK5, ENG and TBR2 mutant embryos all demonstrated severe vascular 
phenotypes at day 10.5, including disappearance of the yolk sac vasculature, speculation 
that they were possibly engaged in the same signaling axis emerged (ten Dijke and Arthur, 
2007). However, using genetically engineered mouse strains carrying the LacZ reporter gene 
under the control of the endogenous ALK1 or ALK5 promoters, Seki and colleagues 
demonstrated that ALK1 was expressed in endothelial cells, whereas ALK5 was expressed in 
VSMC (Seki et al., 2006), suggesting distinct in vivo functions of the two receptors in vascular 
development. Moreover, endothelium-specific genetic deletion of ALK1 during 
embryogenesis triggered severe vascular defects mimicking pathological features of HHT, 
whereas endothelium-specific deletion of TBR2 and ALK5, the two main receptors for TGF, 
presented no detectable phenotype in the developing vasculature (Park et al., 2008). These 
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results suggest that the function of ALK1 in the developing endothelium is independent of 
TGF signaling and that TGF does not play a role in endothelial signaling functions related 
to the onset of HHT like phenotypes (Bailly, 2008). 
 
 
Fig. 6. Models of ALK1 / ENG mediated signaling in endothelial and perivascular cells. 
A. The “Cross-over” model proposes that TGF induces a dual ALK5/SMAD2-3 and 
ALK1/SMAD1-5 phosphorylation response in endothelial cells, whereby ALK1 signaling 
induces endothelial cell proliferation and migration, and antagonizes ALK5 signaling. B. 
The “canonical” TFG model proposes that TGF-induced SMAD2-3 phosphorylation is 
central to perivascular cell biology. TGF may have endothelial functions unrelated to ALK1 
signaling and HHT in vivo and ENG may play a role in transducing canonical TGF 
signaling. C. The BMP9 signaling model proposes that BMP9 is a circulating endothelial 
quiescence factor triggering SMAD1-5 signaling, resulting in endothelial quiescence. 
3.3.2 “Canonical” TGF / pSMAD2-3 signaling model 
In vivo studies have demonstrated a clear role for TGF/ALK5 signaling in vascular 
development (Pardali et al., 2010), but whether TGF signaling impacts endothelial cells in 
vivo remain a matter of controversy since endothelium-specific deletion of ALK5 and TBR2 
do not disrupt the embryonic vasculature (Park et al., 2008). In vitro evidence suggests that 
the “canonical” TGF/SMAD2-3 signaling pathway is operative inside primary cultured 
endothelial cells (Fig. 6B). TGF induces SMAD2-3 phosphorylation in cultured endothelial 
cells (Bostrom et al., 2004; Goumans et al., 2002) and is reported to influence VEGF-A and 
PDGF-B transcript levels (Shao et al, 2009; Cunha et al., 2010). Moreover, ENG is detected in 
association with TBR2 and TGF in primary endothelial cells (Cheifetz et al., 1992; 
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Yamashita et al., 1994); ENG can potentiate “canonical” TGF/ALK5/SMAD2-3 signaling 
(Guerrero-Esteo et al., 2002); and the soluble extra-cellular domain of ENG can inhibit 
binding of TGF to endothelial cells and influence vascular tone (Venkatesha et al., 2006). 
Taken together, these results indicate that TGF may signal in endothelial cells, where it 
may have ALK1-independent, but ENG-dependent functions in the endothelium unrelated 
to the onset of HHT and vascular malformations, but related to the regulation of blood 
pressure (Venkatesha et al., 2006). 
3.3.3 BMP9 / SMAD1-5 signaling model 
An early study pointed to an unknown ligand present in human serum distinct from TGF 
that could activate ALK1 signaling (Lux et al., 1999). Following a report that BMP9 could be 
co-crystalized with ALK1 (Brown et al., 2005), other groups demonstrated that BMP9 and 10 
were the only cognate ALK1 ligands within the TGF super-family (Mitchell et al., 2010) and 
that BMP9 and 10 triggered ALK1/SMAD1-5 signaling in primary endothelial cells (David 
et al., 2007; Scharpfenecker et al., 2007). BMP9 is produced by hepatic endothelial and 
stellate cells and was confirmed to be the ALK1 signaling trigger in human serum (David et 
al., 2008), while BMP10 is only detected during embryonic heart development (Neuhaus et 
al., 1999). BMP9 and 10 are the only TGF super-family ligands to bind ENG in the absence 
of other Type I or II receptors (Scharpfenecker et al., 2007), and ENG potentiates 
BMP9/ALK1/SMAD1-5 signaling in endothelial cells (David et al., 2007). Thus, a new 
model has emerged to explain the signaling pathway that is likely disrupted in the 
endothelium of HHT patients, whereby BMP9 triggers SMAD1-5 phosphorylation through a 
multimeric complex requiring ALK1, BMPR2 or ACTR2B and, possibly, ENG (Fig. 6C). 
3.4 Function of BMP9/ALK1/ENG signaling in endothelial cells in vitro and in vivo 
The response of endothelial cells to BMP9 appears to be context-dependent. In primary 
Human Dermal Microvascular Endothelial Cells (HMVEC-D), obtained from the skin, an 
organ whose vasculature is clearly affected in HHT patients, activation of ALK1 or 
stimulation with BMP9 inhibited cell proliferation and migration, while increasing SMAD1-
5 target gene expression (David et al., 2007; Lamouille et al., 2002). Over-expression of ALK1 
also decreased proliferation of primary HUVEC cells (Ota et al., 2002) and BMP9 blocked the 
proliferative effect of basic FGF (bFGF) on primary endothelial cells (Scharpfenecker et al., 
2007). Based on these in vitro results, and on the fact that BMP9 inhibited vessel formation in 
a bFGF-driven in vivo angiogenesis assay (David et al., 2008), BMP9/ALK1 signaling was 
proposed to function in the resolution phase of angiogenesis, during which endothelial cell 
proliferation and migration shut down and vessel maturation and differentiation proceeds. 
According to this model, disruption of ALK1 signaling leads to endothelial cells that cannot 
stop proliferating and therefore cannot differentiate into mature functional vessels, leading 
to disruption of angiogenesis (David et al., 2009). Given that BMP9 and ALK1 repress the 
expression of pro-angiogenic factors in vitro (Shao et al., 2009) and in vivo (Oh et al., 2000), 
BMP9/ALK1 signaling may be key to the equilibrium between pro- and anti-angiogenic 
signals required for the completion of the activation and resolution phases of angiogenesis, 
which are both required for the formation of a functional vasculature. 
Other studies reached opposite conclusions regarding the role of BMP9/ALK1 signaling in 
endothelial cells, supporting an alternative model in which BMP9 is proangiogenic. Suzuki 
and colleagues described that BMP9 stimulated the proliferation of MESEC cells (Suzuki et 
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al., 2010), while other groups found that ALK1 and ENG stimulated MEEC proliferation 
(Goumans et al., 2002; Lebrin et al., 2004). As stated earlier, immortalized endothelial cells 
such as MESECs or MEECs are probably not the best models to define the physiological 
function of BMP9 and ALK1. However, the fact that BMP9 stimulated angiogenesis in a 
matrigel plug assay and a tumor model in vivo indicates that assay conditions, such as the 
concentration of proangiogenic factors, may influence the endothelium’s response to 
BMP9/ALK1 signaling (Suzuki et al., 2010). 
3.5 Development of therapeutics targeting ENG and ALK1 
Genetic evidence suggests that ENG and ALK1 functionally contribute to tumor 
angiogenesis. Cancer cells implanted in ENG+/- heterozygous mice produced tumors whose 
size and vascularization were reduced by 30% compared with tumors implanted in wild-
type littermates (Duwel et al., 2007). The growth and vascularization of pancreatic neuro-
endocrine tumors were also reduced by ~50% in ALK1+/- mice compared to ALK1+/+ mice 
(Cunha et al., 2010). Together, these studies indicate that blocking ENG or ALK1 function 
could be an effective anti-tumor therapeutic strategy.  
3.5.1 Therapeutic agents targeting ALK1 
Agents targeting ALK1 have entered phase 1 clinical trials, including an ALK1-Fc peptibody 
from Acceleron (RAP-041) (Bendell et al., 2011) and an anti-ALK1 monoclonal antibody 
from Pfizer (Goff et al., 2010). ALK1-Fc sequesters ALK1 ligands such as BMP9 and BMP10 
and inhibits their binding to endothelial ALK1 receptors (Cunha et al., 2010; David et al., 
2007; Mitchell et al., 2010). ALK1-Fc prevented tumor growth in a neuro-endocrine 
pancreatic cancer model, accompanied by a significant decrease in tumor vascularization 
(Cunha and Pietras, 2011). ALK1-Fc also decreased the tumor burden of breast cancer-
implanted mice by 75% (Mitchell et al., 2010), suggesting that RAP-041 may induce an anti-
angiogenic response in cancer patients. Phase 1 results indicate preliminary signs of clinical 
activity but also a potential heart-related toxicity (Bendell et al., 2011). 
The Pfizer antibody (PF-03446962) is a fully human monoclonal antibody that blocks serum-
induced SMAD1-5 phosphorylation in endothelial cells (Hu-Lowe et al., 2011). A surrogate 
anti-mouse Alk1 antibody decreased tumor volume by 70% in a breast cancer model and 
decreased tumor microvascular density, indicating a potent anti-angiogenic effect (Hu-Lowe et 
al., 2011). This antibody was not tested for its ability to inhibit BMP9 signaling specifically, but 
since serum-induced SMAD1 phosphorylation is largely due to the presence of circulating 
BMP9 (David et al., 2008), inhibition of BMP9 signaling is very likely a mechanism of action of 
this antibody. Importantly, the anti-mouse Alk1 antibody significantly improved the efficacy 
of VEGF/VEGFR pathway inhibition in a model of VEGF inhibitor-resistant melanoma, 
indicating the possibility that ALK1 inhibition may overcome mechanisms of resistance to 
VEGF inhibitors (Hu-Lowe et al., 2011). Preliminary evidence of clinical activity of PF-
03446962 has been reported without indications of adverse effects (Goff et al., 2010). 
3.5.2 Therapeutic anti-ENG monoclonal antibodies 
The clinical evaluation of TRC105, a chimeric human IgG1 anti-ENG antibody derived from 
the SN6j monoclonal mouse anti-human ENG antibody, has been initiated. SN6j has an anti-
proliferative effect on human endothelial cells in vitro (She et al., 2004) and decreased tumor 
growth in several mouse tumor models (Tsujie et al., 2006; Uneda et al., 2009). SN6j also 
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inhibited lung and liver metastases in metastatic cancer models (Uneda et al., 2009). The 
anti-tumor mechanism of action of SN6j is thought to derive from its anti-angiogenic 
properties, as SN6j significantly decreased the vascularization of a matrigel plug assay 
(Tsujie et al., 2006). The SN6j antibody has not been tested for its ability to block BMP9 
signaling in endothelial cells, but this possible mechanism of action should be explored. As 
an IgG1 chimeric antibody (Shiozaki et al., 2006), another possible mechanism of action of 
TRC105 could be the engagement of an antibody-dependent cell cytotoxic response (ADCC) 
targeted at the ENG-expressing cancer endothelium (Tsujie et al., 2008). 
The results of a phase 1 trial indicate that TRC105 was well tolerated and there was 
preliminary evidence of clinical responses (Rosen et al., 2010). A phase 1-2 trial conducted in 
castrate-resistant prostate cancer patients confirmed the evidence of clinical responders, 
with patients who had progressed on anti-hormone therapies experiencing a significant 
decrease in PSA levels (Adelberg et al., 2011). Several phase 1 and 2 trials are now planned 
in Bladder, Breast, Renal and Liver cancer, including a combination trial with bevacizumab, 
an anti-VEGF-A antibody. This combination could prove efficacious since VEGF-A 
neutralization induces ENG expression in a pancreatic cancer model (Bockhorn et al., 2003), 
suggesting that ENG-dependent signaling may be engaged in response to VEGF-A 
inhibition as a possible adaptation mechanism. 
4. Conclusions 
In this chapter, we have reviewed signal transduction pathways (NOTCH and 
BMP9/ALK/ENG) whose key functions affect endothelial cell proliferation and vessel 
differentiation. As such, both pathways are critical for the resolution phase of angiogenesis, 
when endothelial cells complete their proliferation and migration in order to form a 
functional vasculature following recruitment of perivascular cells. NOTCH signaling 
determines the cell fate of stalk and tip cells, a step to limit vessel sprouting and allow 
organization into a functional vasculature. Endoglin and ALK1 define a receptor signaling 
complex which transduces BMP9 signaling in ECs. This signaling axis is critical for 
endothelial maturation and homeostasis, since even halving the expression or activity of 
these two proteins leads to hemorrhage and loss of perivascular cells. Both of these 
processes are distinct from the initiation phase of angiogenesis in which VEGF-A plays a 
central role. Therefore agents that interfere with NOTCH and ALK1/ENG signaling (1) are 
predicted to disrupt tumor angiogenesis as monotherapies as suggested by their preclinical 
activity, (2) may prove useful in combination with anti-VEGF inhibitors by targeting distinct 
phases of angiogenesis, provided there is no dose limiting toxicity due to the combination, 
and (3) may be able to overcome intrinsic and acquired resistance mechanisms to anti-VEGF 
therapeutics. With therapeutics to these pathways now progressing in clinical trials, the 
ability to target multiple phases of the angiogenic process to provide increased benefit to 
patients may be tested in the near future. 
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